A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features

被引:96
作者
Rothschild, AJ
Williamson, DJ
Tohen, MF
Schatzberg, A
Andersen, SW
Van Campen, LE
Sanger, TM
Tollefson, GD
机构
[1] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01605 USA
[2] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Harvard Univ, Sch Med, Dept Psychiat, McLean Hosp, Belmont, MA 02178 USA
[4] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA
关键词
D O I
10.1097/01.jcp.0000130557.08996.7a
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this Study was to compare the efficacy and safety of olanzapine (OLZ) monotherapy and an olanzapine/fluoxetine combination (OFC) with placebo (PLA) for unipolar major depression with psychotic features. Under a single protocol, two 8-week, double-blind trials were conducted at 27 sites. Patients (n = 124 trial 1, n = 125 trial 2) were randomized to I of 3 treatment groups: OLZ (5 to 20 mg/d), PLA, or OFC (olanzapine 5 to 20 mg/d + fluoxetine 20 to 80 mg/d). The primary outcome measure was the 24-item Hamilton Depression Rating Scale total score. For trial 1, endpoint improvement for the OLZ group (-14.9) was not significantly different from the PLA or OFC groups. The OFC group had significantly greater endpoint improvement (-20.9) than the PLA group (-10.4, P = 0.001); this significant difference was present within 7 days of therapy and maintained at every subsequent visit. The OFC group also had significantly higher response rate (63.6%) than the PLA (28.0%, P = 0.004) or OLZ (34.9%, P = 0.027) groups. For trial 2, there were no significant differences among treatment groups on the 24-item Hamilton Depression Rating Scale total scores or response rates. The combination exhibited a comparable safety profile with OLZ monotherapy and no significant increases in extrapyramidal symptoms compared with placebo. Patients with major depression with psychotic features treated with OLZ monotherapy did not demonstrate significant depressive symptom improvement compared with placebo in either trial; however, an olanzapine/fluoxetine combination was associated with significant improvement compared with placebo in one trial and was well tolerated.
引用
收藏
页码:365 / 373
页数:9
相关论文
共 39 条
[31]   Review of recent clinical studies with olanzapine [J].
Tollefson, GD ;
Kuntz, AJ .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :30-35
[32]   Olanzapine versus haloperidol in the treatment of schizoaffective disorder - Acute and long-term therapy [J].
Tran, PV ;
Tollefson, GD ;
Sanger, TM ;
Lu, YL ;
Berg, PH ;
Beasley, CM .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :15-22
[33]   Placebo response in studies of major depression - Variable, substantial, and growing [J].
Walsh, BT ;
Seidman, SN ;
Sysko, R ;
Gould, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (14) :1840-1847
[34]  
WILLIAMS LS, 2001, BLUE BOOK PRACT NEUR, V25, P1
[35]  
Zanardi R, 1996, AM J PSYCHIAT, V153, P1631
[36]   Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study [J].
Zanardi, R ;
Franchini, L ;
Gasperini, M ;
Smeraldi, E ;
Perez, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 (04) :195-197
[37]   Venlafaxine versus fluvoxamine in the treatment of delusional depression: A pilot double-blind controlled study [J].
Zanardi, R ;
Franchini, L ;
Serretti, A ;
Perez, J ;
Smeraldi, E .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (01) :26-29
[38]   The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors [J].
Zhang, W ;
Bymaster, FP .
PSYCHOPHARMACOLOGY, 1999, 141 (03) :267-278
[39]   Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex [J].
Zhang, W ;
Perry, KW ;
Wong, DT ;
Potts, BD ;
Bao, JQ ;
Tollefson, GD ;
Bymaster, FP .
NEUROPSYCHOPHARMACOLOGY, 2000, 23 (03) :250-262